State Of Wyoming Rigel Pharmaceuticals Inc Transaction History

State Of Wyoming

$587 Million
Q1 2024

A detailed history of State Of Wyoming transactions in Rigel Pharmaceuticals Inc stock. As of the latest transaction made, State Of Wyoming holds 89,324 shares of RIGL stock, worth $752,108. This represents 0.02% of its overall portfolio holdings.

Number of Shares

89,324

Previous 112,321 20.47%

Holding current value

$752,108

Previous $162,000 18.52%

% of portfolio

0.02%

Previous 0.03%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$1.12 - $1.57 $25,756 - $36,105	-22,997 Reduced 20.47%	89,324 $132,000
Q4 2023 Feb 14, 2024	BUY	$0.72 - $1.56 $18,816 - $40,769	26,134 Added 30.32%	112,321 $162,000
Q3 2023 Nov 14, 2023	BUY	$1.07 - $1.39 $22,176 - $28,809	20,726 Added 31.66%	86,187 $93,000
Q2 2023 Aug 14, 2023	BUY	$1.12 - $1.82 $52,640 - $85,540	47,000 Added 254.59%	65,461 $84,000
Q1 2023 May 12, 2023	SELL	$1.25 - $2.0 $4,623 - $7,398	-3,699 Reduced 16.69%	18,461 $24,000

Q4 2022 Feb 14, 2023	BUY	$0.67 - $1.5 $14,847 - $33,240	22,160 New	22,160 $33,000
Q2 2022 Aug 15, 2022	SELL	$0.67 - $3.19 $1,646 - $7,841	-2,458 Reduced 23.56%	7,975 $9,000
Q1 2022 May 13, 2022	BUY	$2.22 - $3.45 $3,196 - $4,968	1,440 Added 16.01%	10,433 $31,000
Q4 2021 Feb 11, 2022	BUY	$2.36 - $3.57 $11,802 - $17,853	5,001 Added 125.28%	8,993 $24,000
Q3 2021 Feb 11, 2022	BUY	$3.5 - $4.5 $7,840 - $10,080	2,240 Added 127.85%	3,992 $14,000
Q2 2021 Feb 11, 2022	BUY	$3.09 - $4.54 $5,413 - $7,954	1,752 New	1,752 $8,000

Others Institutions Holding RIGL

# of Institutions

122

Shares Held

110M

Call Options Held

556K

Put Options Held

33.9K

View Full List

About RIGEL PHARMACEUTICALS INC

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $1.46B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

More about RIGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wyoming with notifications on news.

Account